ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PRFX vs SBFM // GROSS PROFIT MARGIN

PRF Technologies Ltd. (NASDAQ) VS. Sunshine Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: PRFX 2 — SBFM 5
▲ GROSS PROFIT MARGIN LEADER: SBFM
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRFX VS. SBFM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PRFX SBFM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE -30.00% 33.80% -63.80 SBFM /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -21.40% -13.60 SBFM /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -17.20% -42.80 SBFM /operating-margins <GO>
Net Profit Margin -60.00% -16.50% -43.50 SBFM /net-margins <GO>
Revenue Growth (YoY) — 4.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 SBFM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.6 27.3 +9.27 PRFX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.6M $2.5M $91.0K PRFX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PRFX REV SBFM REV PRFX GROSS % SBFM GROSS % PRFX FCF SBFM FCF
FY 2025 $17.0K $36.3M -50.0% 33.8% -$4.0M -$5.5M
FY 2024 $0 $34.9M — 30.6% -$12.6M -$14.2M
FY 2023 $0 $24.1M — — -$6.7M -$8.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRFX // BETA —
SBFM // BETA —